Medicamen - 2026 Company Profile, Team & Financials

About Medicamen

Medicamen is a publicly listed company based in Delhi (India) founded in 1993. Manufacturer of tablets, capsules, syrups, ointments and ORS. The company has 376 employees. Its Indian entity Medicamen Biotech Limited reported revenue of ₹201 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.

Company details

Medicamen was established in 1993 in Delhi, India, within the pharmaceuticals sector. Finished formulations are developed and produced across two plants, including dedicated blocks for Beta-lactam products, non-Beta-lactam items, Cephalosporin, oral liquids, ORS, iron-folic acid tablets, ointments, and lotions. An in-house RD unit is utilized to standardize various formulations for multiple indications.

Headquarters Delhi, India
Employees 376
Stage Public
Sectors
Healthcare
Website category Health · Biotechnology and Pharmaceuticals
Email
••••••••
Website medicamen.com
Social LinkedIn Facebook Instagram
Legal Name Medicamen Biotech Limited

Operational Areas

Healthcare → Biopharma Outsourcing & Drug Delivery

Key Metrics

Market Cap
₹370 Cr
MEDICAMEQ · NSE
Share Price
₹262.60
-0.21% today
Revenue
₹198 Cr
FY 2025-26 · +21.7% YoY
EBITDA
₹19.59 Cr
Margin 9.9%
Net Profit
₹9.63 Cr
FY 2025-26 · +35.6% YoY
P/E (TTM)
34.0x
P/B 1.3x
Employee Count
376

Associated legal entities of Medicamen

Medicamen is associated with 2 registered companies on The Company Check; the primary company is Medicamen Biotech Limited, a listed company. Each company page carries the filings, financials, charges and directors of that entity.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Medicamen Biotech Limited Listed CIN L74899DL1993PLC056594	Active	22 Dec 1993	New Delhi, Delhi	₹201 Cr	314	13	View details
Gtonic Lifesciences Limited Liability Partnership CIN AAX-1968	Active	29 May 2021	Gurgaon, Haryana			2	View details

Board of directors of Medicamen Biotech Limited (Medicamen)

Medicamen Biotech Limited is the primary company behind Medicamen. The boards of the 2 registered companies of Medicamen currently have 12 directors; the longest-serving is Ashwani Kumar Sharma, appointed in 2015. 30 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Ashwani Kumar Sharma DIN 00325634	Whole-time director	31 Dec 2015	10 yrs 10 mo	Medicamen Biotech Limited
Suresh Kumar Singh DIN 00318015	Director	31 Dec 2015	10 yrs 10 mo	Medicamen Biotech Limited
Rahul Bishnoi DIN 00317960	Director	31 Dec 2015	10 yrs 10 mo	Medicamen Biotech Limited
Sanjay Bansal DIN 00121667	Director	27 Feb 2016	10 yrs 8 mo	Medicamen Biotech Limited
Sumita Dwivedi DIN 08218640	Director	13 Nov 2018	7 yrs 11 mo	Medicamen Biotech Limited
Vimal Kumar Shrawat DIN 08274190	Director	11 Feb 2019	7 yrs 8 mo	Medicamen Biotech Limited
Sangeeta Bishnoi DIN 08288998	Director	11 Feb 2019	7 yrs 8 mo	Medicamen Biotech Limited
Ravi Kumar Bansal DIN 08462513	Director	30 May 2019	7 yrs 5 mo	Medicamen Biotech Limited
Ramit Madan DIN 08071919	Designated Partner	29 May 2021	5 yrs 5 mo	Gtonic Lifesciences Limited Liability Partnership
Gautam Madan DIN 09172459	Designated Partner	29 May 2021	5 yrs 5 mo	Gtonic Lifesciences Limited Liability Partnership
Shaival Saurabh DIN 01971944	Director	12 Aug 2025	1 yr 2 mo	Medicamen Biotech Limited
Sham Goel DIN 02183287	Director	12 Aug 2025	1 yr 2 mo	Medicamen Biotech Limited

IPO & Listings of Medicamen

Medicamen is a publicly listed company on the NSE with ticker symbol MEDICAMEQ in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date27 Oct 2021
Listed onNSE: MEDICAMEQ
Listed entityMedicamen Biotech Limited
Exchange sectorHealth technology
ISININE646B01010
Share price₹295.85 (-0.9% on the day) · 2026-10-14
Market capitalisation₹403 Cr
Price to earnings36.1
EPS (diluted, trailing year)₹8.19
Dividend yield0.34%
Volume (last session)5,873

Financials of Medicamen

Exchange-reported figures of Medicamen Biotech Limited, the listed company behind Medicamen (NSE: MEDICAMEQ).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹198 Cr

+21.7% YoY

EBITDA

₹19.59 Cr

+35.9% YoY

Profit After Tax

₹9.63 Cr

+35.6% YoY

Net Worth

₹276 Cr

+29.3% YoY

Total Assets

₹327 Cr

+31.4% YoY

Total Debt

₹49.20 Cr

+45.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	198	163	179	141	115	113	126
Revenue growth	+21.7%	-9.4%	+27.3%	+22.0%	+2.4%	-10.2%	-
EBITDA	19.59	14.42	23.51	24.35	24.10	19.69	19.46
EBITDA margin	+9.9%	+8.9%	+13.1%	+17.3%	+20.9%	+17.5%	+15.5%
Profit before tax	11.98	9.87	13.08	17.05	18.11	16.41	17.97
Net profit	9.63	7.10	10.94	14.86	14.91	12.14	13.32
Net profit margin	+4.9%	+4.4%	+6.1%	+10.6%	+12.9%	+10.8%	+10.6%
EPS (₹)	7.22	5.59	8.60	11.73	12.19	9.93	10.88
Balance sheet
Total assets	327	249	240	221	174	153	134
Net worth	276	213	207	193	146	133	121
Total debt	49.20	33.77	31.11	25.71	25.80	18.82	11.47
Cash & bank	31.26	3.76	14.79	20.78	3.82	3.89	3.09
Net working capital	179	116	105	106	71.06	55.17	56.76
Cash flow
Cash from operations	(33.17)	(8.16)	(6.74)	(6.29)	4.11	12.77	12.80
Cash from investing	(3.04)	(1.40)	(5.56)	(5.88)	(8.47)	(17.81)	(37.29)
Cash from financing	63.72	(1.47)	6.31	29.13	4.30	5.84	19.06

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	47.90	60.65	46.91	47.17	43.04	29.61	45.14	44.74
Revenue growth (YoY)	+11.3%	+104.8%	+3.9%	+5.4%	-0.0%	-	-	-
Other income	0.86	1.74	0.53	0.37	0.47	5.23	0.14	0.29
EBITDA	4.33	5.44	4.38	5.16	4.61	(1.61)	6.70	5.31
EBITDA margin	+9.0%	+9.0%	+9.3%	+10.9%	+10.7%	-5.4%	+14.8%	+11.9%
Depreciation	1.79	1.73	1.83	1.86	1.80	0.48	2.21	2.61
Interest	0.83	0.38	0.97	0.99	1.15	0.65	0.76	1.04
Profit before tax	2.57	5.07	2.11	2.68	2.13	2.49	3.87	1.95
Tax	0.73	0.61	0.47	0.57	0.53	0.63	0.96	1.05
Net profit	1.84	4.46	1.64	2.11	1.60	1.86	2.91	0.90
EPS (₹)	1.36	3.28	1.21	1.56	1.18	1.47	2.30	0.71

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	179	151	172	138	115	110	117
Revenue growth	+18.1%	-12.1%	+25.0%	+19.4%	+4.8%	-6.1%	-
EBITDA	18.29	17.10	27.24	24.61	24.12	20.03	18.12
EBITDA margin	+10.2%	+11.3%	+15.8%	+17.9%	+20.9%	+18.2%	+15.4%
Profit before tax	11.55	12.77	16.88	17.33	18.13	16.75	16.60
Net profit	9.41	9.44	13.29	15.01	14.93	12.48	12.29
Net profit margin	+5.3%	+6.2%	+7.7%	+10.9%	+12.9%	+11.3%	+10.5%
EPS (₹)	6.94	7.43	10.46	11.86	12.20	10.22	10.03
Balance sheet
Total assets	320	247	241	221	175	154	135
Net worth	280	218	209	194	148	134	122
Total debt	37.85	27.41	29.81	25.71	25.80	18.82	11.47
Cash & bank	31.08	3.58	14.62	20.44	3.81	3.08	2.23
Net working capital	165	108	98.94	102	70.57	54.56	55.95
Cash flow
Cash from operations	(29.26)	(2.63)	(0.25)	(3.50)	4.81	12.98	11.71
Cash from investing	(2.85)	(1.72)	(8.71)	(7.54)	(8.47)	(17.81)	(39.35)
Cash from financing	59.61	(6.68)	3.14	27.67	4.39	5.68	21.36

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	43.85	54.68	43.49	42.23	38.45	26.00	41.14	42.84
Revenue growth (YoY)	+14.0%	+110.3%	+5.7%	-1.4%	-7.3%	-	-	-
Other income	0.86	1.73	0.53	0.37	0.47	5.22	0.14	0.29
Total expenses	39.07	50.55	38.41	37.18	34.41	27.09	34.90	36.30
EBITDA	4.78	4.13	5.08	5.05	4.04	(1.09)	6.24	6.54
EBITDA margin	+10.9%	+7.6%	+11.7%	+12.0%	+10.5%	-4.2%	+15.2%	+15.3%
Depreciation	1.74	1.73	1.75	1.81	1.77	0.47	2.17	2.57
Interest	0.64	0.60	0.78	0.84	0.56	0.62	0.73	1.01
Profit before tax	3.26	3.53	3.08	2.77	2.18	3.04	3.48	3.25
Tax	0.73	0.55	0.48	0.56	0.53	0.63	0.96	0.98

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 05 Nov 2026

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	47.90	60.65	46.91	47.17	43.04	29.61	45.14	44.74
Revenue growth (YoY)	+11.3%	+104.8%	+3.9%	+5.4%	-0.0%	-	-	-
Other income	0.86	1.74	0.53	0.37	0.47	5.23	0.14	0.29
EBITDA	4.33	5.44	4.38	5.16	4.61	(1.61)	6.70	5.31
EBITDA margin	+9.0%	+9.0%	+9.3%	+10.9%	+10.7%	-5.4%	+14.8%	+11.9%
Depreciation	1.79	1.73	1.83	1.86	1.80	0.48	2.21	2.61
Interest	0.83	0.38	0.97	0.99	1.15	0.65	0.76	1.04
Profit before tax	2.57	5.07	2.11	2.68	2.13	2.49	3.87	1.95
Tax	0.73	0.61	0.47	0.57	0.53	0.63	0.96	1.05
Net profit	1.84	4.46	1.64	2.11	1.60	1.86	2.91	0.90
EPS (₹)	1.36	3.28	1.21	1.56	1.18	1.47	2.30	0.71

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	198	163	179	141	115	113	126
Revenue growth	+21.7%	-9.4%	+27.3%	+22.0%	+2.4%	-10.2%	-
Other income	3.11	6.24	2.33	2.46	1.72	0.75	1.94
Total expenses	178	148	156	117	91.35	93.03	106
Employee cost	0.00	30.87	29.07	20.15	14.50	9.00	9.52
EBITDA	19.59	14.42	23.51	24.35	24.10	19.69	19.46
EBITDA margin	+9.9%	+8.9%	+13.1%	+17.3%	+20.9%	+17.5%	+15.5%
Depreciation	7.22	7.07	7.09	6.37	5.77	2.52	2.50
Interest	3.50	3.72	5.67	3.39	1.94	1.51	0.93
Profit before tax	11.98	9.87	13.08	17.05	18.11	16.41	17.97
Tax	2.19	3.32	3.58	2.32	3.20	4.27	4.69
Net profit	9.63	7.10	10.94	14.86	14.91	12.14	13.32
Net profit margin	+4.9%	+4.4%	+6.1%	+10.6%	+12.9%	+10.8%	+10.6%
EPS (₹)	7.22	5.59	8.60	11.73	12.19	9.93	10.88

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	13.56	12.71	12.71	12.65	12.22	12.22	12.22
Reserves & surplus	253	200	194	178	134	121	109
Shareholders' funds (net worth)	276	213	207	193	146	133	121
Minority interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Secured loans	46.40	33.77	31.11	25.71	25.80	18.82	9.97
Unsecured loans	2.80	0.00	0.00	0.00	0.00	0.00	1.50
Total debt	49.20	33.77	31.11	25.71	25.80	18.82	11.47
Total liabilities	327	249	240	221	174	153	134
Assets
Gross block	144	139	137	130	124	116	57.74
Net block	84.66	87.11	91.85	92.66	92.48	89.64	33.69
Capital work in progress	0.00	0.00	0.00	0.00	0.00	0.00	40.50
Investments	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	70.08	62.14	59.38	45.06	27.01	5.20	16.96
Sundry debtors	81.83	68.90	55.26	65.26	63.22	52.55	49.96
Cash & bank balances	31.26	3.76	14.79	20.78	3.82	3.89	3.09
Loans & advances	40.56	29.76	30.18	32.27	28.98	34.39	34.12
Total current assets	224	165	160	163	123	96.03	104
Total current liabilities	44.87	48.12	54.70	57.73	51.97	40.86	47.37
Net working capital	179	116	105	106	71.06	55.17	56.76
Total assets	327	249	240	221	174	153	134

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	3.76	14.79	20.78	3.82	3.89	3.09	8.52
Net cash from operating activities	(33.17)	(8.16)	(6.74)	(6.29)	4.11	12.77	12.80
Net cash from investing activities	(3.04)	(1.40)	(5.56)	(5.88)	(8.47)	(17.81)	(37.29)
Net cash from financing activities	63.72	(1.47)	6.31	29.13	4.30	5.84	19.06
Net change in cash	27.50	(11.03)	(5.99)	16.95	(0.07)	0.80	(5.43)
Closing cash	31.26	3.76	14.79	20.78	3.82	3.89	3.09

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+21.7%	-9.4%	+27.3%	+22.0%	+2.4%	-10.2%	-
EBITDA growth	+35.9%	-38.7%	-3.5%	+1.0%	+22.4%	+1.2%	-
PBT growth	+21.4%	-24.5%	-23.3%	-5.9%	+10.4%	-8.7%	+2.5%
Net income growth	+35.6%	-35.1%	-26.4%	-0.3%	+22.8%	-8.9%	-
Revenue CAGR (3Y)	+12.0%	+12.1%	+16.7%	+3.9%	-2.0%	-	-
EBITDA CAGR (3Y)	-7.0%	-15.7%	+6.1%	+7.8%	+11.3%	-	-
Profitability & leverage
Net income margin	+5.0%	+4.0%	+5.3%	+10.5%	+12.9%	+10.8%	+10.6%
Return on capital employed	-	+5.6%	+8.1%	+10.4%	+12.3%	+12.5%	+16.2%
Return on net worth	-	+3.1%	+4.7%	+8.7%	+10.7%	+9.6%	+12.8%
Debt / equity	-	0.15	0.14	0.15	0.16	0.12	0.11
Long-term debt / equity	-	0.01	0.01	0.02	0.04	0.03	0.01
Interest cover	28.29	50.61	34.53	18.85	10.58	8.79	5.48
Efficiency & per share
Fixed asset turnover	-	1.18	1.34	1.11	0.96	1.30	2.41
Inventory turnover	-	2.68	3.43	3.91	7.17	10.17	7.79
Debtors turnover	-	2.62	2.98	2.19	1.99	2.20	2.69
EPS (₹)	7.22	5.59	8.60	11.73	12.19	9.93	10.88
Dividend per share (₹)	1.00	1.00	1.00	1.00	1.00	1.00	0.50
Book value per share (₹)	0.00	167.57	162.79	150.82	119.89	108.78	99.22

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	43.85	54.68	43.49	42.23	38.45	26.00	41.14	42.84
Revenue growth (YoY)	+14.0%	+110.3%	+5.7%	-1.4%	-7.3%	-	-	-
Other income	0.86	1.73	0.53	0.37	0.47	5.22	0.14	0.29
Total expenses	39.07	50.55	38.41	37.18	34.41	27.09	34.90	36.30
EBITDA	4.78	4.13	5.08	5.05	4.04	(1.09)	6.24	6.54
EBITDA margin	+10.9%	+7.6%	+11.7%	+12.0%	+10.5%	-4.2%	+15.2%	+15.3%
Depreciation	1.74	1.73	1.75	1.81	1.77	0.47	2.17	2.57
Interest	0.64	0.60	0.78	0.84	0.56	0.62	0.73	1.01
Profit before tax	3.26	3.53	3.08	2.77	2.18	3.04	3.48	3.25
Tax	0.73	0.55	0.48	0.56	0.53	0.63	0.96	0.98

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	179	151	172	138	115	110	117
Revenue growth	+18.1%	-12.1%	+25.0%	+19.4%	+4.8%	-6.1%	-
Other income	3.10	6.23	2.30	2.46	1.72	0.75	1.91
Total expenses	161	134	145	113	91.33	90.12	99.22
Employee cost	0.00	21.57	22.12	18.57	14.50	8.79	9.29
EBITDA	18.29	17.10	27.24	24.61	24.12	20.03	18.12
EBITDA margin	+10.2%	+11.3%	+15.8%	+17.9%	+20.9%	+18.2%	+15.4%
Depreciation	7.06	6.96	7.01	6.35	5.77	2.52	2.50
Interest	2.78	3.60	5.65	3.39	1.94	1.51	0.93
Profit before tax	11.55	12.77	16.88	17.33	18.13	16.75	16.60
Tax	2.14	3.33	3.59	2.33	3.20	4.27	4.35
Net profit	9.41	9.44	13.29	15.01	14.93	12.48	12.29
Net profit margin	+5.3%	+6.2%	+7.7%	+10.9%	+12.9%	+11.3%	+10.5%
EPS (₹)	6.94	7.43	10.46	11.86	12.20	10.22	10.03

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	13.56	12.71	12.71	12.65	12.22	12.22	12.22
Reserves & surplus	258	205	196	180	136	122	110
Shareholders' funds (net worth)	280	218	209	194	148	134	122
Secured loans	37.85	27.41	29.81	25.71	25.80	18.82	9.97
Unsecured loans	0.00	0.00	0.00	0.00	0.00	0.00	1.50
Total debt	37.85	27.41	29.81	25.71	25.80	18.82	11.47
Total liabilities	320	247	241	221	175	154	135
Assets
Gross block	142	138	136	130	124	116	57.74
Net block	83.84	86.31	91.11	92.36	92.48	89.64	33.69
Capital work in progress	0.00	0.00	0.00	0.00	0.00	0.00	40.50
Investments	8.06	8.06	7.76	4.08	2.06	2.06	2.06
Inventories	70.08	62.14	59.33	45.06	27.01	5.20	16.96
Sundry debtors	64.91	58.62	48.29	60.23	61.18	49.75	43.93
Cash & bank balances	31.08	3.58	14.62	20.44	3.81	3.08	2.23
Loans & advances	40.05	29.18	30.14	32.24	28.98	34.39	34.12
Total current assets	206	154	152	158	121	92.42	97.24
Total current liabilities	41.57	45.94	53.44	55.62	50.41	37.86	41.29
Net working capital	165	108	98.94	102	70.57	54.56	55.95
Total assets	320	247	241	221	175	154	135

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	3.58	14.62	20.44	3.81	3.08	2.23	8.52
Net cash from operating activities	(29.26)	(2.63)	(0.25)	(3.50)	4.81	12.98	11.71
Net cash from investing activities	(2.85)	(1.72)	(8.71)	(7.54)	(8.47)	(17.81)	(39.35)
Net cash from financing activities	59.61	(6.68)	3.14	27.67	4.39	5.68	21.36
Net change in cash	27.50	(11.04)	(5.82)	16.63	0.73	0.85	(6.29)
Closing cash	31.08	3.58	14.62	20.44	3.81	3.08	2.23

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+18.1%	-12.1%	+25.0%	+19.4%	+4.8%	-6.1%	-
EBITDA growth	+7.0%	-37.2%	+10.7%	+2.0%	+20.4%	+10.5%	-
PBT growth	-9.6%	-24.4%	-2.6%	-4.4%	+8.2%	+0.9%	-5.3%
Net income growth	-0.3%	-29.0%	-11.5%	+0.5%	+19.6%	+1.6%	-
Revenue CAGR (3Y)	+9.1%	+9.5%	+16.1%	+5.5%	-2.0%	-0.4%	+12.5%
EBITDA CAGR (3Y)	-9.4%	-10.8%	+10.8%	+10.7%	+11.4%	+6.1%	+16.1%
Profitability & leverage
Net income margin	+5.3%	+6.2%	+7.7%	+10.9%	+12.9%	+11.3%	+10.4%
Return on capital employed	-	+6.7%	+9.8%	+10.5%	+12.2%	+12.6%	+15.0%
Return on net worth	-	+4.4%	+6.6%	+8.8%	+10.6%	+9.7%	+11.7%
Debt / equity	-	0.13	0.14	0.15	0.16	0.12	0.11
Long-term debt / equity	-	0.00	0.00	0.02	0.04	0.03	0.01
Interest cover	24.76	35.50	27.93	18.57	10.57	8.62	5.95
Efficiency & per share
Fixed asset turnover	-	1.11	1.30	1.08	0.96	1.27	2.25
Inventory turnover	-	2.49	3.30	3.83	7.17	9.94	7.28
Debtors turnover	-	2.83	3.18	2.27	2.08	2.35	2.69
EPS (₹)	6.94	7.43	10.46	11.86	12.20	10.22	10.03
Dividend per share (₹)	1.00	1.00	1.00	1.00	1.00	1.00	0.50
Book value per share (₹)	0.00	171.17	164.54	152.30	121.18	109.98	100.25

Similar companies to Medicamen

Medicamen has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.

Company Name	Domain	Founded	HQ Location	Total funding	Employees	Description
Akums	akums.in	2004	Delhi, India	$70M	395	CDMO focusing on spectrum of dosage forms and therapeutic segments
Jubilant Life Sciences	jubl.com	1978	Noida, India			Company offering a suite of R&D and manufacturing services for small molecules and generics
Nectar Lifesciences	neclife.com	1995	Chandigarh, India	$46.85M	175	Cephalosporin APIs and generic formulations are manufactured.

Premium access

Detailed similar companies of Medicamen

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

Full competitor set
Operating metrics
Benchmarks
Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Medicamen

The website of Medicamen (medicamen.com) receives about 7.4K visits a month and ranks #7,331,578 among all websites worldwide, #6,976 in Biotechnology and Pharmaceuticals.

Monthly visits
7.4K
▲ 345.5% vs previous month
Global rank
#7,331,578
among all websites
Category rank
#6,976
Health · Biotechnology and Pharmaceuticals

Visitor engagement

Bounce rate33%
Pages per visit3.0
Average visit59 sec
Devices
Desktop 40% · Mobile 60%

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Medicamen (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Anthem Biosciences	Developer of integrated contract research development and manufacturing services	2007	Bengaluru, Karnataka, India	USD 35.74 M	USD 226.38 M	2,062
Laurus Labs	Pharmaceutical and biotechnology company	2005	Hyderabad, Telangana, India	USD 229.73 M	USD 726.15 M	12,470
Entero Healthcare	India's leading healthcare products distribution platform	2018	Mumbai, Maharashtra, India	USD 59.67 M	USD 702.49 M	557

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Medicamen

Medicamen Biotech consolidated net profit declines 1.40% in the June 2026 quarter | Capital Market News - Business Standard

Business Standard • 2 months ago

Medicamen Biotech Recommends Final Dividend Of 1 Rupee Per Share For FY Ended March 31, 2026

Reuters • 5 months ago

Medicamen Biotech Gets EU Approval For Registration Of “Paracetamol” From Denmark With XGX Pharma

Reuters • 10 months ago

Medicamen Biotech standalone net profit declines 27.43% in the June 2025 quarter | Capital Market News - Business Standard

Business Standard • 1 year ago

Medicamen Biotech consolidated net profit rises 59.26% in the June 2025 quarter | Capital Market News - Business Standard

Business Standard • 1 year ago

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection | Capital Market News - Business Standard

Business Standard • 1 year ago

Medicamen Bio Standalone December 2024 Net Sales at Rs 41.14 crore, down 6.93% Y-o-Y

Moneycontrol • 1 year ago

Share Market Highlights 12 February 2025: Indian markets extend losing streak amid trade war fears

Thehindubusinessline • 1 year ago

Stock Market Live Updates 12 February 2025: Sensex, Nifty slide on trade war fears; TCS leads tech rally

Thehindubusinessline • 1 year ago

Medicamen Biotech consolidated net profit declines 14.69% in the September 2022 quarter

India Infoline • 1 year ago

Premium access

Complete news archive for Medicamen

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Medicamen

When was Medicamen founded?

Medicamen was founded in 1993.

Where is Medicamen located?

Medicamen is headquartered in Delhi, India. It is registered at Delhi, Delhi, India.

How many employees does Medicamen have?

Medicamen has 376 employees.

What is the annual revenue of Medicamen?

The primary company behind Medicamen, Medicamen Biotech Limited, reported revenue of ₹201 Cr for FY 2026, up 22% year on year.

What does Medicamen do?

Medicamen was established in 1993 in Delhi, India, within the pharmaceuticals sector. Finished formulations are developed and produced across two plants, including dedicated blocks for Beta-lactam products, non-Beta-lactam items, Cephalosporin, oral liquids, ORS, iron-folic acid tablets, ointments, and lotions. An in-house RD unit is utilized to standardize various formulations for multiple indications.

Which companies are similar to Medicamen?

Medicamen's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.

Is Medicamen publicly traded?

Yes, Medicamen is publicly traded on NSE under the ticker symbol MEDICAMEQ.

Which legal entities are associated with Medicamen?

Medicamen is associated with 2 legal entities: Medicamen Biotech Limited, Gtonic Lifesciences Limited Liability Partnership.

Who are the directors of Medicamen?

The legal entities of Medicamen currently have 15 directors, including Ramit Madan, Gautam Madan, Vimal Kumar Shrawat and others.

About Medicamen

Company details

Operational Areas of Medicamen

Associated legal entities of Medicamen

Board of directors of Medicamen Biotech Limited (Medicamen)

IPO & Listings of Medicamen

Financials of Medicamen

Financial Highlights

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr Consolidated Standalone AnnualQuarterly

Financial Statements

Similar companies to Medicamen

Detailed similar companies of Medicamen

Web traffic of Medicamen

Top companies in Biopharma Outsourcing & Drug Delivery

Related news about Medicamen

Complete news archive for Medicamen

Frequently Asked Questions about Medicamen

Financial summary ₹ Cr